TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $134.80.

TMDX has been the subject of several research analyst reports. Evercore ISI assumed coverage on TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price objective for the company. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Needham & Company LLC lifted their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David Weill sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 13,062 shares of company stock worth $1,797,634. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TMDX. PNC Financial Services Group Inc. boosted its position in TransMedics Group by 13.8% during the first quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company’s stock worth $154,000 after purchasing an additional 278 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of TransMedics Group by 2.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 304,367 shares of the company’s stock worth $20,478,000 after buying an additional 6,934 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of TransMedics Group by 104.7% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,309 shares of the company’s stock worth $3,183,000 after buying an additional 24,200 shares during the period. Nuveen LLC purchased a new position in shares of TransMedics Group during the 1st quarter valued at approximately $5,927,000. Finally, Public Sector Pension Investment Board grew its stake in TransMedics Group by 27.4% in the 1st quarter. Public Sector Pension Investment Board now owns 106,480 shares of the company’s stock valued at $7,164,000 after acquiring an additional 22,894 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Up 0.1%

TransMedics Group stock opened at $136.60 on Tuesday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The stock has a market cap of $4.67 billion, a PE ratio of 55.30 and a beta of 2.06. The stock has a 50-day moving average of $125.48 and a two-hundred day moving average of $122.95. TransMedics Group has a one year low of $55.00 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The company had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. During the same period last year, the business earned $0.12 EPS. TransMedics Group’s revenue for the quarter was up 32.2% on a year-over-year basis. On average, research analysts anticipate that TransMedics Group will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.